HC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $18.00 price objective on the stock.

Other analysts have also issued reports about the company. Canaccord Genuity Group restated a “buy” rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday. Finally, Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics has an average rating of “Buy” and a consensus price target of $17.33.

Tenaya Therapeutics Stock Performance

TNYA opened at $1.41 on Wednesday. The firm has a market cap of $111.70 million, a P/E ratio of -0.98 and a beta of 2.72. Tenaya Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $7.01. The firm has a 50-day moving average of $2.45 and a 200 day moving average of $2.73.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Equities research analysts predict that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

Large investors have recently modified their holdings of the company. Synovus Financial Corp purchased a new stake in shares of Tenaya Therapeutics in the third quarter worth $28,000. The Manufacturers Life Insurance Company raised its holdings in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after acquiring an additional 7,000 shares in the last quarter. Algert Global LLC bought a new stake in shares of Tenaya Therapeutics during the 2nd quarter valued at about $74,000. SG Americas Securities LLC purchased a new position in shares of Tenaya Therapeutics during the third quarter worth about $49,000. Finally, XTX Topco Ltd increased its position in shares of Tenaya Therapeutics by 51.2% in the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.